Shares of Celgene Co. (NASDAQ:CELG) have earned an average recommendation of “Buy” from the thirty-four brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, nineteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $115.85.

A number of equities analysts recently weighed in on the stock. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Cann restated a “buy” rating on shares of Celgene in a research report on Monday, December 3rd. Cantor Fitzgerald assumed coverage on shares of Celgene in a research report on Monday, October 1st. They set an “overweight” rating and a $100.00 price target on the stock. Leerink Swann set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a research report on Friday, October 26th. Finally, UBS Group set a $94.00 price target on shares of Celgene and gave the stock a “buy” rating in a research report on Saturday, October 27th.

Hedge funds have recently modified their holdings of the company. HL Financial Services LLC increased its stake in Celgene by 20.5% during the 3rd quarter. HL Financial Services LLC now owns 4,213 shares of the biopharmaceutical company’s stock worth $377,000 after buying an additional 717 shares during the period. FMR LLC increased its stake in Celgene by 26.0% during the 3rd quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock worth $919,890,000 after buying an additional 2,119,257 shares during the period. ING Groep NV increased its stake in Celgene by 116.3% during the 3rd quarter. ING Groep NV now owns 203,229 shares of the biopharmaceutical company’s stock worth $18,187,000 after buying an additional 109,292 shares during the period. Bangor Savings Bank increased its stake in Celgene by 21.2% during the 3rd quarter. Bangor Savings Bank now owns 18,049 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 3,157 shares during the period. Finally, Korea Investment CORP increased its stake in Celgene by 1.5% during the 2nd quarter. Korea Investment CORP now owns 674,446 shares of the biopharmaceutical company’s stock worth $53,565,000 after buying an additional 10,000 shares during the period. Hedge funds and other institutional investors own 72.87% of the company’s stock.

CELG traded down $2.72 on Monday, reaching $70.08. 6,601,676 shares of the company’s stock were exchanged, compared to its average volume of 6,854,144. The firm has a market capitalization of $50.91 billion, a PE ratio of 10.25, a PEG ratio of 0.45 and a beta of 1.50. Celgene has a twelve month low of $66.62 and a twelve month high of $110.81. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 4.06.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.02 by $0.27. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. Celgene had a net margin of 19.64% and a return on equity of 108.76%. As a group, analysts predict that Celgene will post 7.45 earnings per share for the current fiscal year.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Return on Investment (ROI) Defined, Explained

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.